ABSTRACT: MicroRNAs (miRNAs) can regulate cellular differentiation processes by modulating multiple pathways simultaneously. Previous studies to analyze in vivo miRNA expression patterns in developing human limb cartilage tissue identified significant downregulation of miR-483 in hypertrophic chondrocytes relative to proliferating and differentiated chondrocytes. To test the function of miR-483 during chondrogenesis, lentiviral strategies were used to overexpress miR-483 during in vitro chondrogenesis of human bone marrow-derived mesenchymal stem cells (hBM-MSCs). While the in vivo expression patterns led us to hypothesize that miR-483 may enhance chondrogenesis or suppress hypertrophic marker expression, surprisingly, miR-483 overexpression reduced chondrocyte gene expression and cartilage matrix production. In addition, cell death was induced at later stages of the chondrogenesis assay. Mechanistic studies revealed that miR-483 overexpression resulted in downregulation of the TGF-b pathway member SMAD4, a known direct target of miR-483-3p. From these studies, we conclude that constitutive overexpression of miR-483 in hBM-MSCs inhibits chondrogenesis of these cells and does not represent an effective strategy to attempt to enhance chondrocyte differentiation and anabolism in this system in vitro. ß
Human mesenchymal stem cells (MSCs), which can be isolated from a variety of tissues including bone marrow and adipose tissue, are capable of undergoing chondrogenic differentiation and are a strong candidate for tissue engineering approaches to regenerate cartilage for the treatment of osteoarthritis (OA) and other cartilage injuries. [1] [2] [3] However, in vitro chondrogenic differentiation of MSCs also results in expression of markers associated with an endochondral ossificationlike differentiation pathway, including type X collagen and the osteoblastic transcription factor RUNX2, 4,5 and MSC-derived cartilage pellets can ossify when implanted in vivo, limiting their utility. 6 Therefore, strategies that reduce expression of hypertrophic chondrocyte-related markers and/or promote an articular chondrocyte phenotype could improve the clinical value of human MSCs for cartilage regeneration.
One avenue that has shown potential for modulating cellular differentiation is the use of microRNAs (miRNAs), which are important regulators of tissue development and homeostasis. 7, 8 These small RNAs, which are 20-22 nucleotides in length, are generated via a stem-loop structure that is processed into its 5p and 3p strands by the Dicer complex; depending on the miRNA, the 5p, 3p, or both strands may be more abundant. 9, 10 Mature miRNAs are bound by the RNA-induced silencing complex (RISC) and regulate multiple genes simultaneously through complementary interactions with target messenger RNAs (mRNAs), often within the 3 0 untranslated region (3 0 UTR) of the mRNA. 7, 11 These interactions typically destabilize the mRNA, resulting in decreased mRNA levels, or repress protein translation, resulting in decreased protein levels. 12 By regulating many target mRNAs within a cell, a specific miRNA can have profound effects on key signaling pathways. Notably, miRNAs are sufficient for reprogramming of fibroblasts to induced pluripotent stem cells (iPSCs) 13 or for direct conversion of fibroblasts to neurons, 14, 15 demonstrating the utility of miRNAbased strategies for directing cell fate.
Several miRNAs have been demonstrated to influence in vitro chondrogenic differentiation of human MSCs. [16] [17] [18] [19] To identify additional miRNAs that may be important for regulation of chondrogenic differentiation, we previously profiled miRNAs that are highly expressed or differentially expressed within the developing human limb by comparing miRNA expression in proliferating, differentiated, and hypertrophic chondrocytes. 20 This study revealed that miR-483-3p is downregulated 8-and 4.5-fold in hypertrophic chondrocytes relative to proliferating or differentiated chondrocytes, respectively. Interestingly, the 5p strand of miR-483 is also functional and similarly abundant in this context, and recent work demonstrated that miR-483-5p promotes cartilage matrix synthesis in mature chondrocytes. 21 This work, along with several other reports, have found that miR-483 is upregulated in human and mouse OA tissues, possibly suggesting that miR-483 promotes an anabolic response and inhibition of hypertrophic differentiation in an attempt to repair the cartilage tissue. [21] [22] [23] [24] These data led to two hypotheses regarding its function during chondrogenesis: First, that miR-483 could also improve cartilage matrix production during differentiation; and second, that miR-483 could promote differentiation 
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toward an articular phenotype, rather than along the endochondral ossification pathway. To test these hypotheses, we focused on a model of in vitro chondrogenesis using human bone marrow mesenchymal stem cells (hBM-MSCs). In addition to allowing direct comparisons between the previous miRNA profiling study in the developing human limb, this model is especially relevant due to its potential clinical use.
Here, we profiled miR-483-5p and miR-483-3p expression during in vitro chondrogenesis of hBM-MSCs and found that expression in this system does not follow the same patterns as in vivo chondrogenesis. Modulation of miR-483 expression revealed that contrary to its possible pro-chondrogenic function in vivo, miR-483 suppresses chondrogenic differentiation of hBM-MSCs at least in part by targeting SMAD4, a key component of the TGF-b signaling network. Notably, miR-483 overexpression negatively impacted early chondrogenic differentiation, including expression of the master chondrogenic regulator SOX9, and induced robust cell death. Since the early stages of chondrogenic differentiation were inhibited by miR-483 overexpression, we were unable to specifically study the effect of miR-483 on hypertrophic chondrocyte differentiation. These results are informative for cartilage tissue engineering strategies involving human BMMSCs, as we conclude that constitutive overexpression of miR-483 does not improve chondrogenic differentiation or enhance matrix production in this in vitro system.
METHODS

Human MSC Culture and Chondrogenesis Assays
This study was approved by the Washington University Institutional Review Board. hBM-MSCs (Lonza, Walkersville, MD) were expanded in low-glucose DMEM (Gibco, Waltham, MA) containing 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA), 1% penicillin/streptomycin (Sigma), 2 mM L-glutamine (Gibco), and 1 ng/ml FGF-2 (bFGF; Life Technologies, Waltham, MA). Chondrogenic differentiation was performed in three-dimensional pellet culture, 25, 26 using 50,000 cells/pellet for up to 28 days using hBM-MSCs expanded to passage 5. All experiments were performed in the presence of TGF-b3 unless otherwise indicated, and for experiments described as "ÀTGF-b3," chondrogenic medium was prepared as previously indicated, but TGF-b3 was omitted from the medium.
Lentiviral Preparation and Transduction
Genomic sequence containing the pri-miR-483 sequence and approximately 150 nucleotides upstream and downstream of the pri-miRNA sequence was amplified using the miR-483 genomic primers (Table 1) . The pTight backbone (Addgene, Cambridge, MA) was cut with MluI and NotI, and the miR-483 amplicon was inserted using Gibson Assembly Master Mix (New England Biolabs, Ipswich, MA). The integrity of the resulting clones was confirmed by Sanger sequencing. For miR-483 overexpression, pTight, and rtTA lentiviruses (Addgene) 14, 15 were used to overexpress the miR-483 premiRNA or a non-silencing (NS) control. The pTight nonsilencing control is based off of the miR-21 pri-miRNA sequence, but generates a miRNA precursor that is not known to target any human or mouse mRNAs. This plasmid is commercially available via Addgene, and the plasmid sequence is available from this source. Lentiviral stocks were prepared as previously described 14 and were titered using the Lenti-X p24 rapid titer ELISA (Clontech, Mountain View, CA). hBM-MSCs were seeded at 8 Â 10 4 cells/well in 6-well plates and transduced for 48 h at an MOI of 20 using hBM-MSC medium containing 100 mg/ml protamine sulfate (Sigma, Saint Louis, MO). 27 Chondrogenic differentiation was performed as described above in medium containing 0.1 mg/ml doxycycline hyclate (Sigma).
Histology
For assessment of cell death, day 14 pellets were incubated for 20 min with NucGreen488 dye (Life Technologies), embedded in OCT (Tissue-Tek, Sakura Finetek, Torrance, CA), and flash-frozen. Ten micrometer sections were cut, washed once with PBS, and mounted with Fluoro-Gel II containing 4, 6-diamino-2-phenylindole (DAPI; Electron Microscopy Sciences, Hatfield, PA) for imaging. To assess cartilage matrix production, pellets were fixed in 4% paraformaldehyde for 2 h, washed three times with phosphate buffered saline, and dehydrated through increasing concentrations of ethanol before being embedded in paraffin and sectioned (10 mm). Sections were treated with xylene, and rehydrated through decreasing concentrations of ethanol before staining in Weigert's Hematoxylin for 5 min. Slides were washed in running water for 5 min, stained with 0.001% Fast Green for 3 min, rinsed in 1% glacial acetic acid, and stained with 0.1% Safranin O for 5 min. Sliced were then cleared and dehydrated by serial incubations with 95% ethanol, 100% ethanol, and xylene. Mounting medium was applied before coverslipping the sections. For assessment of type II collagen production, day 14 pellets were fixed in paraformaldehyde, embedded, and sectioned as described above. Sections were treated with xylene and rehydrated through decreasing concentrations of ethanol before antigen unmasking by incubation with 10 mg/ml proteinase K (Life Technologies) diluted in 10 mM Tris, pH 7.4 for 20 min at 37˚C. Sections were washed with PBS, blocked with 10% normal goat serum (Sigma) and incubated overnight at 4˚C with 1:100 rat antitype II collagen, 28 which recognizes the triple-helical domain of type II collagen. Sections were washed with PBS and incubated with 1:250 Alexa Fluor 488-labeled goat anti-rat antibody (Life Technologies). Sections were washed with PBS, rinsed with distilled water, and mounted using FluoroGel II containing DAPI as described above.
RNA Extraction and Quantitative PCR
Total RNA was extracted at indicated time points from 10 to 15 pooled chondrogenic pellets using a Total RNA Purification Kit (Norgen Thorold, Ontario, Canada), which isolates both miRNAs and mRNAs. MiRNAs were reverse-transcribed and quantified with TaqMan primer/probe sets (Life Technologies), using the TaqMan microRNA reverse transcription kit (Life Technologies) and TaqMan master mix with no UNG (Life Technologies) using the default TaqMan cycling protocol. Because the TaqMan primer and probe sequences are proprietary, the Assay ID numbers for the TaqMan micro-RNA assays are listed in Table 1 . Messenger RNAs were reverse-transcribed using Superscript RT II (Life Technologies), and quantitative PCR was performed using PowerUp SYBR master mix (Life Technologies) using the default two-
stage cycling protocol (95˚C denaturing, 60˚C annealing). PCR primer sequences are shown in Table 1 . Fold changes were calculated using the 2 ÀDD Ct method. 29 
Western Blotting
Lysates were prepared from 15 pooled day 4 pellets in RIPA buffer composed of 50 mM Tris, pH 8.0 (Sigma), 150 mM sodium chloride (Sigma), 0.5% sodium deoxycholate (Sigma), 0.1% sodium dodecyl sulfate (Sigma), 1% Triton X-100 (Sigma), 1X cOmplete protease inhibitor cocktail (Roche, Basel, Switzerland), and phosphatase inhibitor cocktail (Pierce). 15-20 mg of lysate was resolved by SDS-PAGE and transferred to nitrocellulose membranes. Western blots were performed using mouse anti-bactin (Abcam ab6276, Cambridge, UK), rabbit anti-SMAD4 (Cell Signaling Technologies 38454S, Danvers, MA), and donkey IR680-labeled anti-mouse and IR800-labeled anti-rabbit antibodies (Licor, Lincoln, NE) using the manufacturers' recommendations. All incubations were performed in Odyssey TBS blocking buffer (Licor) containing 0.1% Tween-20. Band intensity was calculated using the Licor Odyssey software and is displayed relative to non-transduced, TGF-b3-treated control pellets or pTight-NS-transduced, TGF-b3-treated pellets cultured in 0.1 mg/ml doxycycline.
Statistical Analyses
For Figure 1A , statistical significance was calculated using Significance of Microarray (SAM) analysis 20 ; Figure 1A , Ã indicates p < 0.05; ÃÃ indicates p < 0.01; ÃÃÃ indicates p < 0.001; and no asterisk indicates p ! 0.05. In Figure 3D -F, experiments are shown separately to show variable responses to omission of TGF-b3; analysis of statistical significance was performed by Student's t-test and showed no significant result.
RESULTS miR-483 is Differentially Expressed During Chondrogenic Differentiation In Vivo but Not In Vitro
We previously profiled miRNA expression in chondrocytes isolated from different regions of the developing human limb, representing proliferating (PC), differentiated (DC), and hypertrophic (HYP) chondrocytes. 20 These data demonstrated a substantial and statistically significant downregulation of miR-483-3p in hypertrophic chondrocytes compared to PC and DC (PC > HYP, 8.19Â ; DC > HYP, 4.53Â; Fig. 1A) . Notably, miR-483-5p is expressed at similar levels to miR-483-3p and is also downregulated in hypertro- (Fig. 1A) , although this difference is not statistically significant.
We next determined whether miR-483 is also differentially expressed during in vitro chondrogenic differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs). Because miR-483 is encoded within an intron of the IGF2 mRNA, we quantified expression of IGF2 in addition to miR-483-5p and -3p throughout differentiation. hBM-MSCs from three independent donors were subjected to chondrogenic differentiation, and RNA was collected from pellets at specific time points, up to 4 weeks of differentiation. As expected, chondrogenic differentiation resulted in substantial upregulation of cartilage matrix genes such as COL2A1 (type II collagen), ACAN (aggrecan), and COMP (cartilage oligomeric matrix protein), as well as the cartilage master transcription factor SOX9 and the microRNA miR-140, which is highly expressed in cartilage and has previously been shown to increase during chondrogenesis of hBM-MSCs (Supplemental Fig. S1A,C) . 16, 30 Expression of markers related to hypertrophic chondrocytes, such as COL10A1 and RUNX2 have previously been shown to be expressed at very early time points during in vitro chondrogenesis of hBM-MSCs, sometimes even earlier than other cartilage matrix genes such as COL2A1. [4] [5] [6] Because expression of these markers does not correlate with bona fide chondrocyte hypertrophy in this model, expression of these markers was not assessed. Lastly, we observe cartilage matrix production at 4 weeks of chondrogenic differentiation as evidenced by positive staining with Safranin O (Supplemental Fig. S1B ), confirming chondrogenic differentiation of hBM-MSCs from these donors.
In contrast to our observations during in vivo development, we found minimal changes in miR-483 expression throughout MSC chondrogenic differentiation: Although a transient upregulation of miR-483-5p is observed during the first 7 days of differentiation, these changes are relatively small and are not significant after correction for multiple comparisons (Fig. 1B) . Similar changes were observed for miR-483-3p (Fig. 1C) , but again none were significant. In addition, we found that miR-483-5p and -3p expression is much lower than miR-140 throughout differentiation (Supplemental Fig. S1C ). Interestingly, IGF2 expression is variable but increases slightly in late stages of differentiation (Fig. 1D) , suggesting that other factors may decouple miR-483 and IGF2 expression levels during chondrogenic differentiation.
miR-483 Overexpression Reduces Chondrogenic Gene Expression and Induces Cell Death
Compared to developing chondrocytes in vivo, miR-483 is very lowly expressed and its expression is not significantly changed during in vitro MSC chondrogenesis. Furthermore, the low expression levels of miR-483 in vitro make this miRNA amenable to overexpression studies but are likely too low to permit inhibition assays. Based on these findings, we hypothesized that increasing miR-483 expression could positively impact in vitro chondrogenic differentiation. Overexpression of miR-483 was accomplished using a doxycycline-inducible lentiviral system, 14, 15 which allows stable, sustained overexpression of both strands of miR-483 or a non-silencing (NS) control, as well as titration of expression levels by variation of doxycycline concentrations. Importantly, this strategy is superior to transient transfection of miRNA mimics, which can lead to extremely high, non-physiological levels of miRNA expression.
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Transduction of hBM-MSCs followed by induction of miR-483 overexpression using a low dose of doxycycline (0.1 mg/ ml) resulted in 10-to 100-fold overexpression of miR-483-5p and -3p in three independent donors, and overexpression was sustained through 2 weeks of chondrogenic differentiation ( Fig. 2A) . Due to the significant variation in endogenous miR-483 expression in NS-transduced pellets, this overexpression was not statistically significant. Importantly, miR-483 expression levels remained near or below those of miR-140 and the moderately abundant miRNA miR-34a at all time points examined (Supplemental Fig. S2A,B; Fig. 2A miR-483 TARGETS SMAD4 TO SUPPRESS CHONDROGENIC DIFFERENTIATION system and occurred due to the low levels of endogenous miR-483.
Assessment of the chondrogenic gene expression of NS-transduced pellets over time demonstrated efficient differentiation of these pellets, as measured by increased expression of the chondrocyte markers COL2A1, ACAN, COMP, and SOX9 (Supplemental Fig. S2C ). This was further validated by positive Safranin O staining and type II collagen immunostaining (Fig. 2B-C, Supplemental Fig.  S2D-E) and confirms previous reports of lentiviral transduction of hBM-MSCs using protamine sulfate. 27 While we hypothesized that miR-483 could have a prochondrogenic effect during in vitro chondrogenesis of hBM-MSCs, assessment of chondrogenic differentiation at 2 weeks demonstrated a clear reduction in both cartilage pellet size and Safranin O staining in miR-483-overexpressing pellets relative to control (NS) pellets ( Fig. 2B; Supplemental Fig. S2D ). Similar findings were observed using immunohistochemical analyses to detect type II collagen ( Fig. 2C ; Supplemental Fig. S2E ). In addition, we observed a substantial increase in cell death at 2 weeks in miR-483-overexpressing pellets relative to control (NS) pellets ( Fig. 2C; Supplemental Fig. S2F ). These results were further validated by analysis of chondrogenic gene expression, as expression of the cartilage matrix genes COL2A1 and ACAN were substantially reduced after 2 weeks of differentiation (Fig. 2D) . Interestingly, we found a significant decrease in expression of the chondrogenic master regulator SOX9, suggesting that this effect may be due to failed initiation of the chondrogenic differentiation program. In contrast to reports demonstrating upregulation of IGF2 expression by miR-483, 32,33 IGF2 expression was not significantly altered by miR-483 overexpression during chondrogenic differentiation of hBM-MSCs. Similarly, we observed no change in COL1A1 (type I collagen) or COMP expression (Fig. 2D) , demonstrating that a specific set of genes are dysregulated by miR-483 overexpression, as opposed to downregulation of all genes examined. While we also posited a potential role for miR-483 in regulating hypertrophic marker expression during in vitro chondrogenesis of hBM-MSCs, we were unable to assess expression of such markers without confounding the effects of miR-483 overexpression on the early stages of chondrogenic differentiation.
miR-483 Suppresses Chondrogenic Differentiation of hBM-MSCs by Targeting SMAD4
In order to examine potential mechanisms by which miR-483 affects chondrogenic differentiation, we focused our efforts on known targets of miR-483-5p or -3p that could regulate cell death during chondrogenesis. While miR-483 can function to suppress apoptosis, 34 miR-483 has also been shown to promote apoptosis by targeting pro-survival genes RAN, API5, and BIRC5 (survivin) in a cancer cell model. 35 A second possibility is suppression of TGF-b signaling, as we have previously found that omission of TGF-b results in cell death during chondrogenic differentiation of hBM-MSCs. 36 Recent work in human trabecular meshwork cells demonstrated a clear role for miR-483-3p in suppressing extracellular matrix production by targeting SMAD4, a key player in TGF-b signaling. 37 While miR-483 only slightly reduces mRNA levels of SMAD4 in this context, stronger effects were observed on SMAD4 protein levels, and this effect was confirmed to be direct using 3 0 UTR-luciferase fusion assays 37, 38 (Fig. 3A) . To test the effect of miR-483 overexpression on these potential targets, we first examined expression in hBM-MSCs overexpressing miR-483 or the NS control that were subjected to 4 or 14 days of chondrogenic differentiation in the presence of TGF-b3 . Interestingly, no significant changes in API5, RAN, or SMAD4 mRNA levels were observed between NSand miR-483-overexpressing cartilage pellets at day 4 or day 14 (Fig. 3B,C) ; the miR-483 target BIRC5 was expressed at levels below the limit of detection in these assays. We observed no change in the endogenous expression of TGFB3 as well (Fig. 3B,C) , suggesting that any dysregulation of TGF-b signaling is not magnified by changes in endogenous TGF-b3 production. In previous work, targeting of both RAN and API5 by miR-483-3p led to downregulation at the mRNA level, although miR-483-mediated suppression of API5 was not statistically significant. 35 Similar effects were observed with the SMAD4 mRNA, and only small changes in expression were observed at day 4 and day 14 (Fig. 3B,C) . However, SMAD4 protein levels at day 4 of chondrogenic differentiation were substantially reduced in miR-483-overexpressing cartilage pellets relative to NS control pellets (Fig. 3D) . Notably, a similar reduction in total SMAD4 protein was observed in pellets in which TGF-b3 was omitted from the chondrogenic medium (Fig. 3D) , suggesting that even a partial reduction of SMAD4 protein could negatively impact chondrogenic differentiation.
DISCUSSION
In this study, we sought to test the function of miR-483 during chondrocyte differentiation. In vivo miRNA profiling of developing human cartilage limb tissue revealed that miR-483 is expressed at moderately high levels in proliferating and differentiating chondrocytes, potentially indicating a function for miR-483 in promoting early chondrocyte differentiation (Fig. 1A   20   ; ). In addition, miR-483-3p is substantially downregulated in hypertrophic chondrocytes relative to earlier developmental stages, suggesting a second possible role in regulating hypertrophic differentiation (Fig. 1A,   20 ). We chose to characterize and modulate miR-483 expression during chondrogenic differentiation of hBMMSCs, as the potential and known functions of miR-483 in chondrocyte differentiation and homeostasis make it an appealing candidate for tissue engineering strategies. It is well-established that hBM-MSCs subjected to in vitro chondrogenic differentiation express genes that typically mark hypertrophic chondrocytes early during the differentiation process, and cartilage pellets generated from in vitro chondrogenic differentiation of hBMMSCs undergo mineralization and vascularization once implanted in vivo. [4] [5] [6] Therefore, strategies that modify the propensity of hBM-MSC-derived cartilage pellets to express these hypertrophy-related markers could provide a useful method to improve the utility of hBMMSCs for regeneration of articular cartilage.
In contrast to the in vivo profiling studies described above, miR-483 is very lowly expressed in hBM-MSCs cultured in monolayer (day 0) and throughout chondrogenic differentiation of hBMMSCs (Fig. 1B,C; Supplemental Fig. S1C ), in agreement with high-throughput profiling studies of miRNA expression during hBM-MSC chondrogenesis. 16, 29 This further suggests that in vitro chondrogenic differentiation of hBM-MSCs does not fully recapitulate in vivo chondrocyte development, as miR-483 expression did not correlate with differentiation state in these assays.
Profiling of endogenous miR-483 expression during in vitro chondrogenic differentiation of hBM-MSCs also clearly demonstrated that miR-483 is amenable to overexpression strategies in this model, but both miRNA strands are expressed at levels that are likely too low to inhibit. Therefore, we implemented a doxycycline-inducible lentiviral system to ensure sustained, physiologically relevant miRNA overexpression throughout the in vitro differentiation assay. 14, 15 Importantly, this method relies on expression of the premiRNA stem-loop, which is processed into the mature miRNAs using the endogenous miRNA processing machinery. Using this method, both the 5p and 3p strands of miR-483 were overexpressed but remained at levels comparable to or lower than the abundant endogenous miRNAs miR-140 and miR-34a, and this overexpression was sustained throughout the duration of the assay ( Fig. 2A, Supplemental Fig. S2A,B) .
Somewhat surprisingly, miR-483 overexpression decreased expression of a panel of chondrocyte markers, including the master regulator of chondrogenesis, SOX9 and the cartilage matrix genes COL2A1 and ACAN, although none of these genes are predicted targets of miR-483-5p or -3p (Fig. 2D) . Some genes were unaffected by miR-483 overexpression, indicating that miR-483 may target a subset of pro-chondrogenic genes. Inhibition of differentiation was further reflected by a substantial reduction in cartilage pellet size and in cartilage matrix production ( Fig. 2B,C ; Supplemental Fig. S2D,E) . However, we were unable to study the effect of miR-483 on expression of hypertrophic markers in this in vitro system, as the early stages of chondrogenic differentiation failed to occur.
Although we were not expecting miR-483 to have such profound deleterious effects on chondrogenic differentiation, these observations provide additional insight into its potential functions and targets when considered in the context of studies in mature chondrocytes. In normal bovine primary chondrocytes in vitro, miR-483 expression was significantly decreased when cells were isolated from their native cartilage matrix, and overexpression of miR-483-5p via a miRNA mimic increased cartilage matrix production by targeting several MAP kinase pathway members. 21 In contrast, recent work examining miR-483-5p modulation in vivo postulates a role for miR-483 in promoting chondrocyte hypertrophy and OA progression by targeting the cartilage matrix protein Matn3 and the matrix metalloproteinase inhibitor Timp2 in a murine model of OA. 39 However, we note that the methods used in this study altered mir-483 expression in other tissues within the murine joint, such as the synovium and meniscus, in addition to cartilage. Therefore, it is challenging to interpret the specific function of miR-483 in chondrocytes specifically as a result. Despite the significant differences in methodologies used to modulate miR-483 expression and in the experimental systems themselves, these studies and the work presented here all point to a clear role for miR-483 in regulating chondrocyte biology. We believe that a likely explanation for the different roles of miR-483 in these experimental contexts lies in differences in the transcriptomes of differentiating hBM-MSCs and mature chondrocytes in vitro and in vivo, which would allow miR-483 to target distinct pools of mRNAs. 40 In addition to its effects on chondrocyte gene expression and matrix production, we also observed that miR-483 overexpression resulted in increased cell death compared to non-silencing controls (Fig. 2D , Supplemental Fig. S2F ). We have previously reported that failure to stimulate the TGF-b pathway by omitting TGF-b during in vitro chondrogenesis of hBM-MSCs similarly results in cell death, 36 although it is not known whether cell death occurs via apoptosis or another mechanism. Other studies have demonstrated that inhibition of chondrogenic differentiation can induce cell death in vivo, as conditional deletion of SOX9 in developing murine limbs resulted in both a block in chondrogenesis and apoptosis.
41 SOX9 expression was significantly reduced in miR-483-overexpressing pellets, so it is possible that a similar mechanism is responsible for the increase in cell death in this model.
Since miR-483 impacted both cell viability and cartilage matrix production, we focused on known miR-483 target genes that have been shown to function in regulating cell death and chondrocyte anabolism. Following miR-483 overexpression, we analyzed the anti-apoptotic genes API5, RAN, and BIRC5, which were shown to be direct targets of miR-483-3p in hepatocellular carcinoma, 35 and the TGF-b pathway member SMAD4, which was reported to be a direct target of miR-483-3p in human trabecular meshwork cells. 37 Interestingly, targeting of SMAD4 by miR-483-3p reduced extracellular matrix production in miR-483 TARGETS SMAD4 TO SUPPRESS CHONDROGENIC DIFFERENTIATION this context, a finding that could be relevant to the study of miR-483 during chondrogenesis. In previous studies, 35 miR-483-3p was shown to downregulate RAN at both the mRNA and protein levels, while its effect on API5 was primarily on protein expression. We found that miR-483 overexpression during hBM-MSC chondrogenesis did not affect RAN expression at any time point examined, suggesting that this miRNA is not regulated by miR-483 in this context (Fig. 3B,C) . Similarly, we found that API5 expression was unaltered by miR-483 overexpression at day 4 of chondrogenic differentiation (Fig. 3B) . While expression was variable at day 14, miR-483 overexpression actually increased API5 expression at day 14 of differentiation in some replicates (Fig. 3C) . These data suggest that direct modulation of apoptosis by miR-483 may not be responsible for the increase in cell death observed at day 14 of chondrogenesis. In contrast, we observed very little change SMAD4 mRNA levels at day 4 or 14 of chondrogenic differentiation (Fig. 3B,C) . However, examination of SMAD4 protein expression at day 4 of chondrogenic differentiation showed that miR-483 overexpression reduced SMAD4 protein levels, and this reduction was similar to that observed when pellets were cultured in the absence of TGF-b3 (Fig. 3D-F) . Together, these data indicate that the suppression of chondrogenic differentiation and induction of cell death by miR-483 during in vitro hBM-MSC chondrogenesis occurs at least in part by repression of SMAD4. However, we note that individual miRNAs can target many genes within a given cell type. We have found one gene that is affected by miR-483 overexpression, but it is likely that miR-483 has many other targets during hBM-MSC chondrogenesis.
While the effects of miR-483 on chondrogenic differentiation of hBM-MSCs were unexpected in light of patterns of differential expression during in vivo chondrogenesis and its function in mature chondrocytes, the observation that miR-483 regulates SMAD4 during in vitro chondrogenesis may provide some clues to its function in vivo. SMAD4 is involved in both TGF-b signaling via SMAD2/3 and BMP signaling via SMAD1/5/8, and it is well-established that SMAD2/3 signaling is required for in vitro MSC chondrogenesis, 42 suggesting that miR-483 could preferentially impact TGF-b signaling in this system. In contrast, SMAD4 plays diverse roles during murine limb development and functions though both the BMP and TGF-b pathways: In the very early stages of limb development, BMP signaling via SMAD4 is required for proper mesenchymal condensation, 43 while in later stages of limb development, TGF-b signaling via SMAD4 inhibits chondrocyte hypertrophy. 44 In vitro murine limb bud micromass cultures 45 would be a reliable way to examine the function of miR-483 and potential regulation of SMAD4, specifically with respect to formation of mesenchymal condensations and regulation of chondrocyte hypertrophy. Preliminary studies suggest that endogenous miR-483 expression may be high enough to allow inhibition or delayed overexpression. These experiments are being pursued in our laboratory, and we expect them to be valuable additions to the studies of miR-483 function in cartilage development or homeostasis.
